Business
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
Keli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease SOUTH SAN FRANCISCO,
About this update from Spruce Biosciences, Inc.
[{"type":"text","content":"\nKeli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nSpruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Keli Walbert to the Company's Board of Directors.\n\n“Keli joins the Board of Directors at a pivotal time as we prepare for a Biologics License Application for TA-ERT for the treatment of Sanfilippo Syndrome Type B (MPS IIIB),” said Michael Grey, Executive Chairman of Spruce Biosciences. “Her experience in successfully launching multiple drugs and her deep understanding of the rare disease commercial landscape will help support our transition into a commercial-stage organization focused on delivering potentially the first disease-modifying therapy for children with MPS IIIB.”\n\nMs. Walbert has more than 20 years of experience leading teams across commercial functions, including marketing and sales, market access, patient services, advocacy, digital, market research and analytics and operations. She has deep therapeutic experience across immunology, rheumatology, dermatology, gastroenterology, ophthalmology, nephrology, neurology and obesity/metabolic diseases, with a particular strength in rare disease commercialization. Ms. Walbert most recently served as Executive Vice President, U.S. Commercial, at Horizon Therapeutics, where she was responsible for driving commercial strategy and organizational development for more than 10 marketed brands across nephrology, ophthalmology and rare disease, among other therapeutic areas. Prior to this position, she held numerous roles of increasing responsibility at Horizon, including leading the launch of the blockbuster medicine TEPEZZA for thyroid eye disease. Before joining Horizon, Ms. Walbert held leadership roles at AbbVie, American Medical Association, Abbott and United Healthcare. Ms. Walbert has received numerous awards and recognitions including the Luminary Award from the Healthcare Businesswomen's Association and the MM+M Women of Distinction Award. She received a master's degree from Northwestern University and a bachelor of arts degree from the University of...